I'm wondering whether we are seeing the evolution of the drug business and if our number is coming up.

With the number of drugs that are coming to the end of their patent life could their patents be extended as a combination with apabetalone? The patent on APB is apparently good until 2040 which would make these 8 and 10 billion annual sales mongsters able to produce for their owners as a combo for an additional 12 to 14 years past their current patent expiries.

The question is, is it now worth it for one or more of these companies with cardio and or diabetes drugs to take APB to market despite any potential encroachments on other products they currently have on the shelf?

would like to hear your thoughts.

tada